Citigroup
LEXX icon

Citigroup’s Lexaria Bioscience LEXX Stock Holding History

Citigroup’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$381 Buy
+489
New +$355 ﹤0.01% 5550
2025
Q4 		– Sell
-429
Closed -$409 – 6283
2025
Q3 		$409 Buy
+429
New +$415 ﹤0.01% 5724
2022
Q3 		– Sell
-1,230
Closed -$4K – 6106
2022
Q2 		$4K Buy
+1,230
New +$3.3K ﹤0.01% 5689

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Citigroup's LEXX Position: Q1 2026 in Review

Citigroup opened a new position in Lexaria Bioscience (LEXX) in Q1 2026: 489 shares worth $381. The stake represents ﹤0.01% of the portfolio and ranks #5550 among its holdings. This is a return to the name: Citigroup previously reported a position in LEXX as recently as Q3 2025.

Citigroup first reported a position in LEXX in Q2 2022 and has held it in 3 quarters since. The position peaked at $4K in Q2 2022. 28 funds tracked by Wall St. Rank hold LEXX as of Q1 2026.

  • Citigroup held 489 shares of Lexaria Bioscience worth $381 as of Q1 2026.
  • Lexaria Bioscience was a new Citigroup position in Q1 2026.
  • Lexaria Bioscience made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5550 holding.
  • Citigroup first reported a position in Lexaria Bioscience in Q2 2022 and has held it in 3 quarters since.
  • Citigroup's Lexaria Bioscience position peaked at $4K in Q2 2022.
  • 28 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.